Belgian biopharma UCB said final trials of Cimzia, a potential blockbuster drug for Crohn's disease, yielded "significant positive" results. The company plans to apply within nine months to start selling the drug in Europe and the US. UCB said both phase III trials assessing the safety and efficacy of Cimzia had achieved "statistical significance" compared to the control groups in the trials and showed that the drug is "highly effective" at reducing Crohn's symptoms. UCB is also working to get approval to market Cimzia to treat rheumatoid arthritis.
- read this press release for more